代謝型グルタミン酸受容体3(GPRC1C/MGLUR3/GRM3)の世界市場:パイプラインレビュー(2018下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA906A244)
◆英語タイトル:Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2018
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA906A244
◆発行日:2018年8月14日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[代謝型グルタミン酸受容体3(GPRC1C/MGLUR3/GRM3)の世界市場:パイプラインレビュー(2018下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Pipeline Review, H2 2018
Summary

According to the recently published report ‘Metabotropic Glutamate Receptor 3 – Pipeline Review, H2 2018′; Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors.

Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory auto receptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.

The report ‘Metabotropic Glutamate Receptor 3 – Pipeline Review, H2 2018′ outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System and Oncology which include indications Depression, Glioma, Pervasive Developmental Disorder (PDD), Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Impairment, Neurodegenerative Diseases, Parkinson’s Disease, Schizophrenia, Smoking Addiction and Treatment Resistant Depression.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Overview
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
AstraZeneca Plc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Co
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Drug Profiles
AEVI-004 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8529 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010991 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-011088 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-341495 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize mGLUR3 for Glioma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0650786 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Dormant Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Discontinued Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-001
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Aevi Genomic Medicine Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Denovo Biopharma LLC, H2 2018
Pipeline by Domain Therapeutics SA, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

*** 掲載企業 ***

Addex Therapeutics Ltd、Aevi Genomic Medicine Inc、AstraZeneca Plc、Denovo Biopharma LLC、Domain Therapeutics SA、Eli Lilly and Co

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 自動車用LiDARセンサーの世界市場2016-2020
    About the Automotive LiDAR Sensors Market LiDAR (light detection and ranging) sensing is a technology that measures distance by illuminating a target with a laser light. In automobiles, LiDAR sensors are largely used to automate driving of vehicles through obstacle detection and avoidance, which wou …
  • 美容医療レーザーの世界市場予測2019-2024
    Aesthetic Medicine Lasers have not only specialized in the field of beauty, but also extends to a series of fields that are in line with the public's aesthetics, such as skin, dentistry and ophthalmology. According to this study, over the next five years the Aesthetic Medicine Lasers market will reg …
  • 世界のスマートバッテリー市場2017
    Smart Battery Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, …
  • 工業用触媒の世界市場:石油精製、化学合成、石油化学・ポリマー用途
    About the Industrial Catalysts Market Catalysts accelerate a chemical reaction by providing an alternative route with lower activation energy. This results in a higher reaction rate for the same reactant concentrations and at the given temperature compared with uncatalyzed reactions. Industrial cata …
  • 世界の空心コイル市場2017
    Air Core Coil Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, …
  • パイナップル缶詰の世界市場予測2019-2024
    Pineapple is a tropical plant. Pineapple contains a proteolytic enzyme bromelain, which digests food by breaking down protein. It is also a good source of manganese as well as contains significant amounts of Vitamin C and Vitamin B1. The Canned Pineapple Slices & Chunks can be prepared juices, soft …
  • リソグラフィ装置の世界市場2016
    The Global Lithography Systems Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Lithography Systems industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain str …
  • 自動車用酸素センサーの世界市場:製品別(狭帯域ジルコニアセンサー、広帯域ジルコニアセンサー、チタニアセンサー)、用途別(乗用車、商用車、2輪車)、地域別予測
    Global Automotive Oxygen Sensor Market to reach USD XXX billion by 2025. Global Automotive Oxygen Sensor Market valued approximately USD XXX billion in 2016 is forecasted to grow with a healthy growth rate of more than XX% over the forecast period 2018-2025. The major factors speculated to augment t …
  • インスタントティーミックスの世界市場2016
    The Global Instant Tea Premix Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Instant Tea Premix industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain struc …
  • 世界の安全シューズ市場2016
    2016 Global Work/Safety Shoes Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Work/Safety Shoes industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and Chin …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA906A244 )"代謝型グルタミン酸受容体3(GPRC1C/MGLUR3/GRM3)の世界市場:パイプラインレビュー(2018下半期)" (英文:Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2018)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。